PL3455631T3 - Sposoby klasyfikowania pacjentów z nowotworem litym - Google Patents

Sposoby klasyfikowania pacjentów z nowotworem litym

Info

Publication number
PL3455631T3
PL3455631T3 PL17725195T PL17725195T PL3455631T3 PL 3455631 T3 PL3455631 T3 PL 3455631T3 PL 17725195 T PL17725195 T PL 17725195T PL 17725195 T PL17725195 T PL 17725195T PL 3455631 T3 PL3455631 T3 PL 3455631T3
Authority
PL
Poland
Prior art keywords
classification
patients
methods
solid cancer
cancer
Prior art date
Application number
PL17725195T
Other languages
English (en)
Inventor
Jérôme GALON
Bernhard Mlecnik
Franck Pages
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Sorbonne Universite
Université de Paris
Assistance Publique - Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Sorbonne Universite, Université de Paris, Assistance Publique - Hôpitaux De Paris filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of PL3455631T3 publication Critical patent/PL3455631T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6862Ligase chain reaction [LCR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17725195T 2016-05-09 2017-05-09 Sposoby klasyfikowania pacjentów z nowotworem litym PL3455631T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer
EP17725195.6A EP3455631B1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (1)

Publication Number Publication Date
PL3455631T3 true PL3455631T3 (pl) 2021-04-06

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17725195T PL3455631T3 (pl) 2016-05-09 2017-05-09 Sposoby klasyfikowania pacjentów z nowotworem litym

Country Status (13)

Country Link
US (1) US20190309369A1 (pl)
EP (1) EP3455631B1 (pl)
JP (3) JP7281903B2 (pl)
KR (1) KR102245021B1 (pl)
CN (2) CN115198018A (pl)
AU (1) AU2017261685B2 (pl)
ES (1) ES2808004T3 (pl)
MX (1) MX393482B (pl)
PL (1) PL3455631T3 (pl)
RU (1) RU2745730C2 (pl)
SG (1) SG11201809317VA (pl)
WO (1) WO2017194556A1 (pl)
ZA (1) ZA201807020B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11430545B2 (en) 2017-06-13 2022-08-30 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
JP7554779B2 (ja) * 2019-06-03 2024-09-20 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル 処置レジメンを調節する方法
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
JP7741831B2 (ja) * 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
EP4330676A1 (en) * 2021-04-27 2024-03-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
JP2024517986A (ja) * 2021-05-13 2024-04-23 セントリックスバイオ インコーポレイテッド 抗-CD300c抗体を利用した併用療法
AU2022447608A1 (en) 2022-03-17 2024-09-26 Assistance Publique - Hôpitaux De Paris Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
JP2025520176A (ja) * 2022-06-03 2025-07-01 ウニヴェルシタ・デグリ・ストゥディ・ディ・ローマ・ラ・サピエンツァ 転移性腎癌患者における予後スコアの決定法
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097B (zh) * 2023-10-25 2024-06-07 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119291200A (zh) * 2024-10-16 2025-01-10 华中科技大学同济医学院附属协和医院 一种用于检测cxcr4+cd8+t细胞用于预测肿瘤免疫治疗的检测试剂盒
CN120259410B (zh) * 2025-06-05 2025-09-23 北京大橡科技有限公司 基于双Panel多重生物标志物分析的肿瘤免疫响应可能性的评分方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601795A4 (en) * 2003-03-07 2008-03-26 Threshold Pharmaceuticals Inc METHOD FOR DETERMINING THE SENSITIVITY OF A TUMOR AGAINST TREATMENT WITH AN ANTI-TUMBER AGENT
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
WO2010120814A1 (en) * 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP2619576B1 (en) * 2010-09-24 2020-06-10 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US9945861B2 (en) * 2012-01-20 2018-04-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for predicting the survival time of a patient suffering from a solid cancer based on density of B cells
WO2013186374A1 (en) 2012-06-14 2013-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for quantifying immune cells in tumoral tissues and its applications
US11242564B2 (en) * 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
TR201819211T4 (tr) * 2012-08-06 2019-01-21 Hopitaux Paris Assist Publique Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler
CA2900969A1 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
ES2755165T3 (es) * 2013-07-15 2020-04-21 Univ Paris Descartes Método para el pronóstico del tiempo de supervivencia de un paciente que padece un cáncer sólido

Also Published As

Publication number Publication date
MX2018013744A (es) 2019-08-16
BR112018072993A8 (pt) 2022-11-22
RU2018143409A3 (pl) 2020-06-29
CN109690314B (zh) 2022-08-02
ZA201807020B (en) 2020-05-27
CN115198018A (zh) 2022-10-18
MX393482B (es) 2025-03-24
AU2017261685B2 (en) 2023-09-07
JP2024019551A (ja) 2024-02-09
RU2018143409A (ru) 2020-06-10
ES2808004T3 (es) 2021-02-25
BR112018072993A2 (pt) 2019-03-06
KR20190016025A (ko) 2019-02-15
US20190309369A1 (en) 2019-10-10
EP3455631A1 (en) 2019-03-20
CN109690314A (zh) 2019-04-26
KR102245021B1 (ko) 2021-04-26
JP2019516979A (ja) 2019-06-20
JP7281903B2 (ja) 2023-05-26
WO2017194556A1 (en) 2017-11-16
EP3455631B1 (en) 2020-06-24
RU2745730C2 (ru) 2021-03-31
JP7654318B2 (ja) 2025-04-01
SG11201809317VA (en) 2018-11-29
JP2022027788A (ja) 2022-02-14
AU2017261685A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
PL3455631T3 (pl) Sposoby klasyfikowania pacjentów z nowotworem litym
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
IL258955A (en) Compositions and methods for treatment of cancer
EP3402517A4 (en) Immunologic treatment of cancer
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
PL3240801T3 (pl) Skojarzona immunoterapia nowotworów
IL252361A0 (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
PL3283527T3 (pl) Leczenie skojarzone nowotworów
GB201616912D0 (en) Classification of cancer
HUE059694T2 (hu) Készítmény rák kezelésére
PL3060237T3 (pl) Zmodyfikowane białko przeprogramowujące do stosowania w leczeniu raka
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL263802A (en) Cancer treatment combinations
HUE038541T2 (hu) Rák kezelési módszerek
IL253160B (en) Cancer markers and methods of use thereof
PL3198009T3 (pl) Onkolityczne wirusy nowotworowe i sposoby zastosowania
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
PT3622953T (pt) Tratamento combinado do cancro
PL3525774T3 (pl) Leczenie lazofoksyfenem raka piersi er+
EP3413927A4 (en) CANCER THERAPY